Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Must Resolve Breakpoint Issues On Road To Ceftaroline Approval

Executive Summary

Negotiation of breakpoints appears to be the final hurdle as Forest Laboratories seeks approval for ceftaroline fosamil to treat serious skin infections and community-acquired bacterial pneumonia.
Advertisement

Related Content

FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline
FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
CABP Clinical Response Endpoint Gets A Boost At Ceftaroline Advisory Panel
Forest's Ceftaroline Data Robust Even Under New Antibiotic Efficacy Standards, FDA Says
FDA Should Outsource Elements Of Antibacterial Labeling Updates - Cmte.
FDA Should Outsource Elements Of Antibacterial Labeling Updates - Cmte.

Topics

Advertisement
UsernamePublicRestriction

Register

PS052606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel